Immutep’s Pipeline: Progress in Immunotherapy and Autoimmune Treatments
[videojs_video url=’https://du7x25at22z7c.cloudfront.net/IV_Immutep_250307/single_720p.mp4′ poster=’http://www.finnewsnetwork.com.au/newssystem/seqcmsfiles/2025/03/vFRzvGhtDnjaSpePUFV8_1920x1080_31003.jpg’]
Immutep (ASX:IMM) CEO Marc Voigt discusses the company’s latest advancements in immunotherapy and autoimmune treatments. A key focus is the TACTI-004 trial, a large-scale Phase III study for first-line non-small cell lung cancer, conducted in collaboration with Merck, across more than 25 countries. Success in this trial could set a new standard of care.
The company’s TACTI-003 trial for head and neck cancer has shown promising results in progression-free and overall survival, with upcoming discussions with the FDA on the next steps.
Immutep has fully recruited its AIPAC-003 trial for breast cancer and is analyzing data to determine the optimal dosage.
Beyond oncology, the company is developing IMP761, a treatment for autoimmune diseases, with early-stage safety data looking positive and further results expected mid-year.
Financially, Immutep recently joined the ASX 300. Key upcoming milestones include regulatory interactions, new trial data, and continued progress in recruitment for its pivotal studies.
Copyright 2025 – Finance News Network
Source: Finance News Network
